WeVote
Log In

Bill

Bill

SB 1236

Controlled Substances - As introduced, removes Tetrahydrocannabinolic acid (THCa) and Tetrahydrocannabiphorol (THCp) from the list of authorized hemp-derived cannabinoids. - Amends TCA Title 39, Chapter 17, Part 4 and Title 43, Chapter 27.

114th Regular Session (2025-2026) Introduced by Ferrell Haile

Tennessee bill removes THCa and THCp from authorized hemp products, closing legal loopholes that allowed intoxicating cannabinoid sales without cannabis-level regulation.

Placed on Senate Finance, Ways, and Means Committee calendar for 4/21/2026
#controlledsubstances
0
WeVote Research Nonpartisan
Bill Summary · SB 1236

Legislative bill overview

SB 1236 removes two cannabinoids—THCa (tetrahydrocannabinolic acid) and THCp (tetrahydrocannabiphorol)—from Tennessee's list of legally authorized hemp-derived products. Currently, these compounds exist in a legal gray area as hemp derivatives, but this bill would prohibit their sale and production in the state. The legislation amends Tennessee's controlled substances and hemp regulations.

Why is this important

THCa and THCp products have become commercially significant in states where cannabis remains restricted, as they can produce psychoactive effects similar to traditional marijuana while operating under hemp loopholes. This bill directly addresses a regulatory gap that has allowed widespread retail sales of intoxicating products without the licensing, testing, or tax frameworks applied to regulated cannabis. The decision affects a growing industry, consumer access, and how states regulate cannabis-adjacent products.

Potential points of contention

  • Industry impact: Removing authorization eliminates a legal business sector generating retail sales; affected businesses and entrepreneurs may face losses or legal uncertainty
  • Federalism and hemp law complexity: THCa exists naturally in hemp; distinguishing legal hemp from illegal controlled substances creates enforcement challenges and may conflict with federal hemp regulations that don't explicitly ban these compounds
  • Consumer access and medical use claims: Some users assert these products have therapeutic value; restriction limits access for those in non-legalized cannabis states without addressing whether evidence supports medical claims

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.